ArticleBMC neuroscience2010
Immunohistological detection of Chlamydia pneumoniae in the Alzheimer's disease brain.
Article in BMC neuroscience, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 72 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
72 citing papers in PubMed, 159 citations in OpenAlex.
- A critical review on the roles of natural products in shaping oral microbiota and preventing chronic diseases.Natural products and bioprospecting · 2026Review
- Identification of Chlamydia pneumoniae and NLRP3 inflammasome activation in Alzheimer's disease retina.Nature communications · 2026Article
- The oral - X axis: from periodontal dysbiosis to systemic disease.Frontiers in immunology · 2026Review
- Article
- Bridging oral and systemic health: exploring pathogenesis, biomarkers, and diagnostic innovations in periodontal disease.Infection · 2025Review
- The association of common infectious exposures with cognitive performance in community-dwelling older adults.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Infections withFrontiers in aging neuroscience · 2025Review
- The amyloid-beta wave hypothesis of Alzheimer's disease.Frontiers in cellular and infection microbiology · 2025Article
- Smoking Impacts Alzheimer's Disease Progression Through Oral Microbiota Modulation.Molecular neurobiology · 2025Review
- Regional Differences in Microbial Infiltration of Brain Tissue from Alzheimer's Disease Patients and Control Individuals.Brain sciences · 2024Article
- Review
- Herpes simplex virus 2 serology is associated with thinner whole-brain cortex in community-dwelling older adults.Journal of the neurological sciences · 2023Article
- Systemic Inflammation Causes Microglial Dysfunction With a Vascular AD phenotype.Brain, behavior, & immunity - health · 2023Article
- Emerging role of gut microbiota dysbiosis in neuroinflammation and neurodegeneration.Frontiers in neurology · 2023Review
- Exploring the Mechanisms and Association between Oral Microflora and Systemic Diseases.Diagnostics (Basel, Switzerland) · 2022Review
- Infectious origin of Alzheimer's disease: Amyloid beta as a component of brain antimicrobial immunity.PLoS pathogens · 2022Review
- The gut microbiome and Alzheimer's disease: Complex and bidirectional interactions.Neuroscience and biobehavioral reviews · 2022Review
- Repurposing of intestinal defensins as multi-target, dual-function amyloid inhibitorsChemical science · 2022Article
- Does Dementia Have a Microbial Cause?NeuroSci · 2022Review
- Clinical and Preclinical Studies of Fermented Foods and Their Effects on Alzheimer's Disease.Antioxidants (Basel, Switzerland) · 2022Review
12 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSporadic late-onset Alzheimer's disease (AD) appears to evolve from an interplay between genetic and environmental factors. One environmental factor that continues to be of great interest is that of Chlamydia pneumoniae infection and its association with late-onset disease. Detection of this organism in clinical and autopsy samples has proved challenging using a variety of molecular and histological techniques. Our current investigation utilized immunohistochemistry with a battery of commercially available anti-C. pneumoniae antibodies to determine whether C. pneumoniae was present in areas typically associated with AD neuropathology from 5 AD and 5 non-AD control brains.
resultsImmunoreactivity for C. pneumoniae antigens was observed both intracellularly in neurons, neuroglia, endothelial cells, and peri-endothelial cells, and extracellularly in the frontal and temporal cortices of the AD brain with multiple C. pneumoniae-specific antibodies. This immunoreactivity was seen in regions of amyloid deposition as revealed by immunolabeling with two different anti-beta amyloid antibodies. Thioflavin S staining, overlaid with C. pneumoniae immunolabeling, demonstrated no direct co-localization of the organism and amyloid plaques. Further, the specificity of C. pneumoniae labeling of AD brain sections was demonstrated using C. pneumoniae antibodies pre-absorbed against amyloid β 1-40 and 1-42 peptides.
conclusionsAnti-C. pneumoniae antibodies, obtained commercially, identified both typical intracellular and atypical extracellular C. pneumoniae antigens in frontal and temporal cortices of the AD brain. C. pneumoniae, amyloid deposits, and neurofibrillary tangles were present in the same regions of the brain in apposition to one another. Although additional studies are required to conclusively characterize the nature of Chlamydial immunoreactivity in the AD brain, these results further implicate C. pneumoniae infection with the pathogenesis of Alzheimer's disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.